Colon
FDA approves second blood-based colorectal cancer screening test

  • August 11

Liver
Zalfermin adds no fibrosis benefit to semaglutide in phase 2 MASH trial

  • August 11

Liver
Prior ascites, encephalopathy flag high mortality after variceal bleeding

  • August 10

Liver
Liver cancer risk after HBsAg loss varies sharply by age and cirrhosis, study finds

  • August 7

Liver

Lean steatosis without metabolic risk factors tied to liver-related death

  • August 12

“Clinicians should consider patients with steatosis but without cardiometabolic risk factors or harmful alcohol use as a distinct entity that may still carry liver-related risk.”

BROWSE BY TOPICS

The New Gastroenterologist

Substance use disorders in gastroenterology and hepatology: A practical guide for the general gastroenterologist

  • August 3

  • by Isabelle S. Byers, MD, Michelle Russin, MD, Sasha Deutsch-Link, MD, MSCR

GI and liver complications often bring these patients in first, and the authors say gastroenterologists are well placed to screen and treat.

Esophagus
Bridging the rural divide: Building a motility center in a critical access hospital

  • August 3

  • by Amber Charoen, MD, W. Michael McDonnell, MD, AGAF

“If large urban centers can run comprehensive motility labs, why can't a critical access hospital?”

Is professional coaching worth it? A practical guide for early-career gastroenterologists

  • August 3

  • by Mariam Naveed, MD, FACG, Kathryn E. Hutchins, MD, FACG

Two program directors on why coaching belongs at the start of a GI career, not after something has already gone wrong.

The Latest

August 12
Liver
Lean steatosis without metabolic risk factors tied to liver-related death

  • by Doug Brunk

“Clinicians should consider patients with steatosis but without cardiometabolic risk factors or harmful alcohol use as a distinct entity that may still carry liver-related risk.”

August 11
Liver
Zalfermin adds no fibrosis benefit to semaglutide in phase 2 MASH trial

  • by Doug Brunk

Semaglutide monotherapy outperformed placebo on the primary endpoint, including in compensated cirrhosis, but investigators say the finding is nominal.

August 11
Colon
FDA approves second blood-based colorectal cancer screening test

  • by Bob Alaburda

Freenome's SimpleScreen CRC detected roughly 8 in 10 cancers in the PREEMPT CRC trial — but just 13.7% of advanced precancerous lesions, the performance gap that keeps blood tests out of guideline-preferred status.

August 10
Liver
Prior ascites, encephalopathy flag high mortality after variceal bleeding

  • by Doug Brunk

Two-year mortality was 25.1% in patients with prior decompensation vs. 13.5% in those without, but the excess risk was confined to those with prior ascites or hepatic encephalopathy.

August 7
Liver
Liver cancer risk after HBsAg loss varies sharply by age and cirrhosis, study finds

  • by Meg Barbor

Annual HCC incidence ranged from 0.03% in patients without cirrhosis who cleared HBsAg before age 50 to 0.62% in those with cirrhosis aged 50 or older.